Atrys Health (STU:A2T) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


STU:A2T Atrys Health SA STU:A2T
68 GF Score
Price €2.57
GF Value €3.10
! 5 Warning Signs
View Full Analysis

What is Atrys Health Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Atrys Health's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

STU:A2T vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Atrys Health's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atrys Health Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrys Health's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Atrys Health's Margin of Safety % (DCF Earnings Based) falls into.


STU:A2T
68GF Score
Atrys Health SA STU:A2T
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Atrys Health (STU:A2T) Overvalued in 2026?

Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued. The current stock price of €2.57 is trading 17.1% below its estimated GF Value™ of €3.10.

Key valuation signals for STU:A2T:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €3.10 vs. price of €2.57 (17.1% below fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the STU:A2T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atrys Health Business Description

Other Exchanges ATRY:SpainA2T:Germany
Address Calle Provenca, 392 planta baja, Barcelona, ESP, 08025
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
68GF Score

Get the complete analysis for STU:A2T

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.57
Price
€3.10
GF Value